Dr. Marshall R. Posner, associate editor of The Oncology Report, discusses research highlights from the Multidisciplinary Head and Neck Cancer Symposium, including the emerging molecular picture of head and neck cancer and the growing awareness of HPV prevalence in the U.S. population.

Keep visiting The Oncology Report for more head and neck cancer news. »

SAN ANTONIO – Dr. Howard A. Burris III, Dr. William J. Gradishar, and Dr. Hope S. Rugo remark on the implications of the CLEOPATRA trial, in which the addition of pertuzumab to a standard chemotherapy combination of trastuzumab and docetaxel led to an additional 6 months of progression-free survival in patients with HER2-positive metastatic breast cancer,... »

SAN ANTONIO – Dr. Howard Burris, Dr. William J. Gradishar, and Dr. Hope Rugo discuss the implications of the BOLERO-2 trial, which coupled everolimus with exemestane in women with advanced hormone resistant, estrogen receptor-positive breast cancer.

 »

SAN ANTONIO – The Oncology Report's editor-in-chief, Dr. Howard A. Burris III, and its associate editor Dr. William J. Gradishar discuss an ONCOTYPE DX assay for ductal carcinoma in situ at the 2011 San Antonio Breast Cancer Symposium.

 »

SAN ANTONIO – Dr. Hope S. Rugo, associate editor of The Oncology Report, discusses the use of bisphosphonates as antitumor agents in early-stage breast cancer at the 2011 San Antonio Breast Cancer Symposium.

 »

SAN ANTONIO – Dr. William J. Gradishar and Dr. Hope S. Rugo, associate editors of The Oncology Report, discuss fulvestrant and anastrazole as first-line therapy for postmenopausal women with hormone receptor-positive breast cancer.

 »

SAN ANTONIO – Dr. William J. Gradishar, associate editor of The Oncology Report, discusses the conflicting results from multiple clinical trials over the last decade and whether bisphosphonates reduce cancer recurrence and metastatic risk.

 »

SAN DIEGO – Dr. Kenneth C. Anderson, associate editor of The Oncology Report, discusses new therapies for multiple myeloma and changing risk factors in presentations at the 2011 annual meeting of the American Society of Hematology (ASH).

 »

Dr. Hope Rugo says we define triple-negative disease by what it is not; we need to treat what it is.

 »

Is there a future for antiangiogenic therapy with hormone therapy in hormone receptor-positive breast cancer? Dr. Hope Rugo discusses a failed sorafenib trial in the last of 3 video commentaries from the European Multidisciplinary Cancer Congress in Stockholm.

 »

Dr. Hope Rugo discusses the practice-changing BOLERO-II trial of everolimus and exemestane in ER-positive breast cancer. »

Dr. Hope Rugo discusses new comparative data on T-DM1 in HER2-positive breast cancer. »

Much controversy exists in determining the appropriate treatment for patients with localized gastroesophageal cancers. Contributing factors include differences in epidemiology of these cancers in different areas of the world, which lead to differences in behavior of these cancers and potentially in responses to therapy; inconsistent control for the type of... »

This disappointment was almost palpable; the promise of iniparib, combined with gemcitabine and carboplatin, was not realized in the large phase III trial performed to confirm the strikingly positive data from the randomized phase II trial. In a twist of coincidence, the data from the phase II trial were published in the New England Journal of Medicine 2... »

BY JUDD W. MOUL, M.D.

The National Comprehensive Cancer Center guidelines are extremely useful for clinicians practicing cancer care. While the guidelines offer great advice and update the literature on various patterns of care, they are guidelines, however, and as such do offer some flexibility in the way individual clinicians manage their individual... »